[Effects of UFT in advanced XXXX ].

@entity1 @entity417 @entity5 @entity294 @entity1358 @entity74 @entity3 @entity1487
Clinical trials of UFT have been conducted on @entity1 with far-advanced @entity1358 with distant @entity3 . All @entity1 had evaluable lesions which had shown no change or progressive disease under prior therapy. Five of these cases had received Interferon as prior therapy. Thus far, the antitumor effects of the drug were evaluated in 8 cases according to the criteria proposed by the Koyama-Saito group. Partial response was obtained in 3 of 8 @entity1 (37.5%). Two @entity1 showed no change and three @entity1 showed @entity74 caused @entity417 and @entity294 in each of @entity1 . To measure the @entity1487 level in the @entity5 and normal kidney tissues UFT was administered at 600 mg per day on the day before radical nephrectomy in 2 @entity1 , who had received embolization therapy of the renal artery prior to surgery. The @entity1487 level was higher in @entity5 and normal kidney tissues than in serum, but there was no significant difference between @entity5 and normal kidney tissues. The embolization therapy of the renal artery may have been responsible for this result. UFT is one of the most useful drugs for the treatment of @entity1358 .
